Supernus Pharmaceuticals (NASDAQ:SUPN) Director Georges Gemayel Sells 8,787 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 8,787 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $53.00, for a total value of $465,711.00. Following the completion of the transaction, the director directly owned 27,277 shares in the company, valued at approximately $1,445,681. This represents a 24.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Georges Gemayel also recently made the following trade(s):

• On Thursday, March 5th, Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.71, for a total value of $537,100.00.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $54.17 on Tuesday. The stock has a 50-day simple moving average of $51.05 and a two-hundred day simple moving average of $48.90. The firm has a market capitalization of $3.12 billion, a PE ratio of -79.66, a P/E/G ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $59.68.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $62.17.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Sit Investment Associates Inc. grew its holdings in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after buying an additional 250 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after buying an additional 277 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in shares of Supernus Pharmaceuticals by 3.6% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock worth $415,000 after acquiring an additional 290 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.